Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J M Kane

Showing results (1-10 of 249) with videos related to

Pageof 25
Sort By:
Psychopharmacology Bulletin|January 1, 1992
Biologic, pharmacologic, and psychosocial factors influencing response to neurolepticsJ M Kane
The Journal of Clinical Psychiatry|May 1, 1994
Risperidone: new horizons for the schizophrenic patient. 9th World Congress of Psychiatry of the World Psychiatric Association, Rio de Janeiro, June 1993J M Kane
L'Encephale|December 1, 1996
[Clozapine in the treatment of schizophrenia]J M Kane
The Journal of Clinical Psychiatry|January 1, 1996
Treatment-resistant schizophrenic patientsJ M Kane
The British Journal of Psychiatry. Supplement|December 1, 1996
Factors which can make patients difficult to treatJ M Kane
The American Journal of Psychiatry|July 1, 1977
Improvement or relief from side effectsJ M Kane
Psychiatric Medicine|January 1, 1990
Psychopharmacologic treatment issuesJ M Kane
The Journal of Clinical Psychiatry|May 1, 1985
Antipsychotic drug side effects: their relationship to doseJ M Kane
The Journal of Clinical Psychiatry|May 1, 1984
The use of depot neuroleptics: clinical experience in the United StatesJ M Kane
The British Journal of Psychiatry : the Journal of Mental Science|April 1, 1994
The use of higher-dose antipsychotic medication. Comment on the Royal College of Psychiatrists' consensus statementJ M Kane
Pageof 25

Showing results (1-10 of 249) with videos related to

Sort By:
Pageof 25
Psychopharmacology Bulletin|January 1, 1992
Biologic, pharmacologic, and psychosocial factors influencing response to neurolepticsJ M Kane
The Journal of Clinical Psychiatry|May 1, 1994
Risperidone: new horizons for the schizophrenic patient. 9th World Congress of Psychiatry of the World Psychiatric Association, Rio de Janeiro, June 1993J M Kane
L'Encephale|December 1, 1996
[Clozapine in the treatment of schizophrenia]J M Kane
The Journal of Clinical Psychiatry|January 1, 1996
Treatment-resistant schizophrenic patientsJ M Kane
The British Journal of Psychiatry. Supplement|December 1, 1996
Factors which can make patients difficult to treatJ M Kane
The American Journal of Psychiatry|July 1, 1977
Improvement or relief from side effectsJ M Kane
Psychiatric Medicine|January 1, 1990
Psychopharmacologic treatment issuesJ M Kane
The Journal of Clinical Psychiatry|May 1, 1985
Antipsychotic drug side effects: their relationship to doseJ M Kane
The Journal of Clinical Psychiatry|May 1, 1984
The use of depot neuroleptics: clinical experience in the United StatesJ M Kane
The British Journal of Psychiatry : the Journal of Mental Science|April 1, 1994
The use of higher-dose antipsychotic medication. Comment on the Royal College of Psychiatrists' consensus statementJ M Kane
Pageof 25